Human papillomavirus vaccines to prevent cervical cancer

Lancet

Volumn 369, Issue 9576, 2007, Pages 1837-1839

  Markman, Maurie ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; WART VIRUS VACCINE;

ARTICLE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG COST; FEVER; HEALTH CARE DELIVERY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; INJECTION SITE DISCOMFORT; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VIRUS INFECTION;

EID: 34249663315     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(07)60828-9     Document Type: Note

References (20)

1. Parkin D., Bray F., Ferlay J., and Pisani P. Global cancer statistics, 2002. CA-A Cancer J Clinicians 55 (2005) 74-108
2. Waggoner S. Cervical cancer. Lancet 361 (2003) 2217-2225
3. Adami H.-O., Ponten J., Sparen P., et al. Survival trend after invasive cervical cancer diagnosis in Sweden before and after cytologic screening. Cancer 73 (1994) 140-147
4. Katz I., and Wright A. Preventing cervical cancer in the developing world. N Engl J Med 354 (2006) 1110
5. Frazer I. Prevention of cervical cancer through papillomavirus vaccination. Nat Rev Immunol 4 (2004) 46-54
6. Castle P., Solomon D., Schiffman M., and Wheeler C. Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities. J Natl Cancer Inst 97 (2005) 1066-1071
7. Khan M., Castle P., Lorincz A., et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18. J Natl Cancer Inst 97 (2005) 1072-1079
8. Koutsky L., Ault K., Wheeler C., et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 347 (2002) 1645-1651
9. Villa L., Costa R., Petta C., et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 6 (2005) 271-278
10. The FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 356 (2007) 1915-1927
11. The Future II Study Group. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 369 (2007) 1861-1868
12. Joura E., Leodolter S., Hernandez-Avila M., et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 369 (2007) 1693-1702
13. Garland S., Hernandez-Avila M., Wheeler C., et al. Quadrivalent vaccine against human papilloma virus to prevent anogenital diseases. N Engl J Med 356 (2007) 1928-1943
14. Harper D., Franco E., Wheeler C., et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364 (2004) 1757-1765
15. Harper D., Franco E., Wheeler C., et al. Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367 (2006) 1247-1255
16. Collins Y., Einstein M., Gostout B., et al. Cervical cancer prevention in the era of prophylactic vaccines: A preview for gynecologic oncologists. Gynecol Oncol 102 (2006) 552-562
17. Bjorge T., Engeland A., Luostarinen T., et al. Human papillomavirus infection as a risk factor for anal and perianal skin cancer in a prospective trial. Br J Cancer 87 (2002) 61-64
18. Agosti J., and Goldie S. Introducing HPV vaccine in developing countries-key challenges and issues. N Engl J Med 356 (2007) 1908-1910
19. Gostin L., and DeAngelis C. Mandatory HPV vaccination: Public health vs private wealth. JAMA 297 (2007) 1921-1923
20. Zimmerman R. Ethical analysis of HPV vaccine policy options. Vaccine 24 (2006) 4812-4820